Navigation Links
Novan's SB204 Could Be First Topical Sebum Inhibitor
Date:2/28/2013

DURHAM, N.C., Feb. 28, 2013 /PRNewswire/ -- Novan Therapeutics, a clinical-stage drug development company, today announced in vitro and animal testing data indicating that the company's drug candidate, SB204, could lead to a topical treatment to reduce oil production in the skin.  SB204 is being developed as a new therapy for acne which is the most common skin disease in the United States, affecting more than 50 million people. 

(Logo: http://photos.prnewswire.com/prnh/20130228/NE68367LOGO )

None of the current topical products approved by the FDA reduce the production of sebum, the oily/waxy secretions of the skin.  Dr. Diane Thiboutot , Professor of Dermatology at Penn State Hershey College of Medicine, believes "Inhibiting the production of sebum is critical to affecting the acne disease process.  Orally administered therapies that can reduce oily secretions of the skin have traditionally shown good clinical responses.  At this time, I am not aware of any topically applied therapy that can reduce sebum production."

Novan-sponsored research conducted in the lab of Dr. Thiboutot revealed that nitric oxide-releasing compounds could reduce sebum production in vitro using immortalized human sebocytes.  The study results demonstrated that Novan's drug candidate showed a statistically significant decrease in insulin-induced lipid production as early as 24 hours after a single treatment.   

In a separate study to further expand upon the company's unique discovery, topical application of nitric oxide-releasing SB204 inhibited the growth of a hamster flank organ by more than 50% compared to vehicle control.  "We are really excited about these results because this now gives us two potential pathways by which SB204 can shut down the production of sebum in the skin," said company President Dr. Nathan Stasko .  The golden Syrian hamster flank organ model has historically been used to assess the anti-androgenic activity of experimental therapeutics.  The overproduction of androgens in the skin has been linked to the overproduction of sebum and worsening of acne.

Novan expects to begin enrolling subjects in a Phase 2 study for the treatment of acne in the second quarter of this year.  This clinical study will evaluate the safety and efficacy of SB204 as well as the topical therapy's ability to decrease sebum in the skin of subjects.  Dr. Stasko commented, "We have invested significant resources to develop methods for the clinical evaluation of sebum in the skin.  SB204 could be an attractive topical acne treatment and what we believe will be the first of many innovative products for the field of dermatology."

About Novan, Inc.

Novan Inc., based in the Research Triangle Park area of North Carolina, is a clinical-stage drug development company harnessing the power of nitric oxide.  Nitric oxide, one of the most studied molecules in human physiology, has been confirmed to promote vasodilation, regulate inflammation, revitalize tissue, kill invading microorganisms, and even eradicate cancer.  The company's proprietary platform technology enables the stable storage of nitric oxide and the ability to deliver its healing power to patients in a variety of dosage forms.  Novan is currently developing innovative, first-in-class therapies for the field of dermatology. 

For more information, please contact:

Julia Brannan 
Pascale Communications 
201-725-7375 
novan@pascalecommunications.com  
www.novantherapeutics.com


'/>"/>
SOURCE Novan Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Report: Drugstore Networks Could Save Employers, Medicare, and Medicaid $115 Billion
2. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
3. Pen Pals, Glowing Parasites & Crop Camouflage Could Help Improve Lives
4. Back to School Ideas: Vaccines for Kids Could Hurt Rather Than Help Fight Disease
5. HIV Immunity Study Could Pave Way for Vaccine Development
6. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
7. Ochsner Implants First Total Artificial Heart In The Gulf South Region
8. London Health Sciences Centre Announces Firsts in Treatment Option for Blood Circulation
9. Ixonos auttaa Firstbeatia parantamaan syketallentimensa suorituskykyä ja helppokäyttöisyyttä
10. Ixonos Helps Firstbeat to Boost the Performance and Usability of Their Heart Beat Recording Device
11. New Bioterrorism Vaccine Gets First Test In Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
(Date:5/26/2016)... Angeles, CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide ... videos available to both Snapchat users and those who do not use the app. Dr. ... on his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Lung ... host a six-week smoking cessation class starting June 6 at their clinic in downtown ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
Breaking Medicine News(10 mins):